FDA Reevaluates 12 Peptides After RFK Jr. Challenge to 2023 Ban
The U.S. Food and Drug Administration (FDA) is set to reevaluate twelve peptides following a challenge from Robert F. Kennedy Jr. This pivotal review will take place during meetings on July 23 and 24, 2023. Experts express concerns that Kennedy may influence advisory board decisions to favor his agenda.
FDA’s Concerns Over Peptides
Previously, in 2023, the FDA removed 19 peptides from the list designated for compounding pharmacies. This decision highlighted significant safety concerns associated with these compounds. The agency noted potential risks for each peptide, emphasizing the need for thorough scientific evaluation before consideration for human use.
Upcoming Review of Peptides
The advisory committee will examine the following seven peptides:
- BPC-157
- KPV
- TB-500 (thymosin beta-4 fragment)
- MOTs-C
- Emideltide (DSIP)
- Semax (heptapeptide)
- Epitalon
The remaining five peptides will be reviewed in February 2027:
- Cathelicidin (LL-37)
- GHK-Cu
- Dihexa-acetate
- Melanotan II
- Mechano Growth Factor, Pegylated (PEG-MGF)
Public Concerns About Peptide Use
Experts like Robert Steinbrook, director of the Health Research Group at Public Citizen, warn against using alternative pathways for approval. He criticizes the potential bypassing of rigorous FDA processes. Steinbrook argues that if the peptides were genuinely safe and effective, substantial evidence would already be accessible.
The FDA currently lists certain uses for these peptides, but they often differ from how users are marketing them. For instance, BPC-157 is known in fitness circles for promoting tissue repair, despite being officially noted for treating ulcerative colitis. This discrepancy raises further questions about the regulation and application of these substances.
As the FDA prepares for this critical reevaluation, the implications of their findings could significantly impact how peptides are accessed and utilized in healthcare and wellness industries.
